FGFR News

News

Bemarituzumab Added to Chemotherapy Significantly Benefits Survival in FGFR2b-Positive Gastric and GEJ Cancer

10/20/2025

Stephanie Holland

Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...

Results from the phase 3...

10/20/2025

Oncology

FDA Approval

FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations

01/20/2024

Stephanie Holland

Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.

Based on results from cohort 1...

01/20/2024

Oncology

News

Pemigatinib Effective, Safe Among Patients With Unresectable or Metastatic Urothelial Carcinoma With FGFR3 Genetic Alterations

12/19/2023

Allison Casey

Final results from the phase 2 FIGHT-201 trial found pemigatinib demonstrated clinical activity and tolerable safety among patients with unresectable or metastatic urothelial carcinoma with FGFR3 genetic alterations.

Final results from the phase 2...

12/19/2023

Oncology

News

Erdafitinib Prolonged Overall Survival Among Patients With FGFR-Altered Metastatic Urothelial Carcinoma Treated With Checkpoint Inhibitors

12/01/2023

Allison Casey

According to the phase 3 THOR trial, erdafitinib prolonged overall survival among patients with FGFR-altered metastatic urothelial carcinoma who had previously received treatment with anti–PD-1/L1 agents, compared with chemotherapy.

According to the phase 3 THOR...

12/01/2023

Oncology

News

Pemigatinib Shows Potential for First Effective Treatment for FGFR1-Mutant Myeloid, Lymphoid Neoplasms

03/09/2022

Results of the ongoing FIGHT-203 trial show pemigatinib for FGFR1-mutant myeloid and lymphoid neoplasms may be a bridge for HSCT or a long-term treatment option for those ineligible for transplant.

Results of the ongoing FIGHT-203...

03/09/2022

Oncology

News

Pan-FGFR TKI Shows Favorable Efficacy in Advanced Urothelial Cancer

02/25/2022

Erdafitinib continues to show efficacy with longer follow-up for patients with locally advanced or metastatic urothelial carcinoma and prespecified FGFR alterations.

Erdafitinib continues to show...

02/25/2022

Oncology

News

Pemigatinib, A Selective FGFR Inhibitor, Safely Treats Hematologic Malignancies

02/23/2022

Results from the FIGHT-101 trial confirm pemigatinib was safe and tolerable in patients with FGFR mutant hematologic malignancies. These findings prompted phase 2/3 trials in multiple tumors that will benefit from this precision therapy.

Results from the FIGHT-101 trial...

02/23/2022

Oncology

Recent News

News

Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise

01/29/2026

Stephanie Holland

Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...

Results from a real-world...

01/29/2026

Oncology

News

Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer

01/29/2026

Emily Estrada

The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.

The addition of elenagen to...

01/29/2026

Oncology

News

Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma

01/28/2026

Stephanie Holland

Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.

Results from the phase 1/2...

01/28/2026

Oncology

News

Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer

01/27/2026

Gina Tomaine

Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.

Antibody-based therapies are...

01/27/2026

Oncology

News

Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial

01/27/2026

Emily Estrada

Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.

Tucatinib plus trastuzumab...

01/27/2026

Oncology

News

TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC

01/27/2026

Emily Estrada

A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.

A TOMOX-bevacizumab combination...

01/27/2026

Oncology

News

ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC

01/27/2026

Gina Tomaine

A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.

A translational study identified...

01/27/2026

Oncology

News

CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT

01/26/2026

Gina Tomaine

Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.

Systemic CSF-1R inhibition...

01/26/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer

01/22/2026

Stephanie Holland

Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...

Results from the phase 3...

01/22/2026

Oncology

News

Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer

01/21/2026

Stephanie Holland

Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...

Results from a multicenter,...

01/21/2026

Oncology